Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.

Maclean C. Sellars Jessica A. Frank Bohoon Shim Allison P. Vanasse Ruo-Lin Liu Cleo Forman Chloe R. Tu Kyohei K. Tabata Antonia Kowelewski Su-Chun Cheng Catherine Song Kan Xiong Pia Jain Andjela Crnjac Haley E. Sax Vipheaviny A. Chea Wesley S. Lu J. Janes M. Rickles-Young A. Sud Savni Sarolkar Martin Hayes Oriol Olive Haley Greenslade C. Cibulskis N. Hacohen E. Fritsch Shu-Qiang Li K. Livak N. Tayob Elizabeth H. Stover Carolyn N. Krasner Rebecca L. Porter U. Matulonis Gad Getz Giacomo Oliveira P. Ott Jeremy M. Simon V. Adalsteinsson Derin B. Keskin Panagiotis A. Konstantinopoulos Catherine J. Wu
Oct 2026 · Nature Medicine · 0 citations · 36 references
Medicine

TL;DR

The interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy following vaccination, and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination.

DOI PubMed Semantic Scholar
View source

Similar papers

Review Oct 2026

Strategies to develop therapeutic cancer vaccines for pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies. Conventional immunotherapies have shown little clinical benefit, largely due to the low neoantigenicity and profoundly immunosuppressive microenvironment of this cancer. Therapeutic cancer vaccines have emerged as a rational strategy to...

Matilde M. Coppi, Michele Graciotti, Antonia Digklia et al. · 0 citations
Open access Oct 2026

mRNA-Based Therapy in Melanoma, Personalized Neoantigen Vaccines and the Future of Precision Immunotherapy

Improvements in both recurrence-free survival and distant metastasis-free survival for the combination of intismeran autogene and pembrolizumab compared with pembrolizumab alone are reported, representing an important milestone for mRNA-based cancer therapy.

Iliyan Pochileev · 0 citations
Review Open access Sep 2026

Developing neoantigen cancer vaccines: where are we now?

This review examines recent advances in neoantigen cancer vaccine development, highlighting clinical progress across cancer types while discussing ongoing challenges and opportunities to enhance vaccine design, delivery, and combination immunotherapy approaches.

N. Markosyan, Robert H. Vonderheide · 0 citations
Review Open access Sep 2026

Synergistic Antitumor Activity of Personalized mRNA Neoantigen Vaccines and PD-1/PD-L1 Inhibitor in Solid Tumors

Immunotherapy for cancer now represents a breakthrough in treatment of solid tumors. However, the clinical efficacy of immune checkpoint inhibitors is still limited by insufficient tumor-specific immune activation and multiple immune escape mechanisms. Personalized mRNA vaccines based on neoantigens offer an encouragin...

Zhen-Li He · 0 citations
Review Open access Oct 2026

Emerging landscape of antibody-drug conjugates in lung cancer: a clinical review.

Lung cancer is a heterogeneous disease, and while targeted therapies and immunotherapies have improved patient outcomes, 5-year overall survival remains poor at approximately 20%. Antibody-drug conjugates (ADCs) target tumors using a targeted antibody that delivers a cytotoxic payload with clinically proven antitumor a...

Henry Pickett, J. Arias-Romero, Jeremy Fricke et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.